EP300 and urinary bladder carcinoma: For example, one could envision a trial of a combination of a checkpoint inhibitor with a BET inhibitor in bladder cancers with high TMB and EP300 mutations, while patients with high TMB and DNA damage response defects could be assigned to a checkpoint inhibitor with PARP inhibitor arm.